Difference between revisions of "Stub"
Line 30: | Line 30: | ||
*[[Bortezomib (Velcade)]] | *[[Bortezomib (Velcade)]] | ||
*[[Siltuximab (Sylvant)]] | *[[Siltuximab (Sylvant)]] | ||
+ | |||
+ | ==BTH (Taxotere)== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | BTH: '''<u>B</u>'''evacizumab, '''<u>T</u>'''axotere (Docetaxel), '''<u>H</u>'''erceptin (Trastuzumab) | ||
+ | ===Regimen=== | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] | ||
+ | ====Targeted therapy==== | ||
+ | *[[Bevacizumab (Avastin)]] | ||
+ | *[[Trastuzumab (Herceptin)]] | ||
==Carboplatin & Epirubicin== | ==Carboplatin & Epirubicin== |
Revision as of 00:28, 20 August 2020
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon unless new evidence comes forward. This page is primarily to drive the Ontology.
Abiraterone & Enzalutamide
back to top |
Regimen
Hormonotherapy
Bortezomib & Bevacizumab
back to top |
Regimen
Targeted therapy
Bortezomib & Siltuximab
back to top |
Regimen
Targeted therapy
BTH (Taxotere)
back to top |
BTH: Bevacizumab, Taxotere (Docetaxel), Herceptin (Trastuzumab)
Regimen
Chemotherapy
Targeted therapy
Carboplatin & Epirubicin
back to top |
Regimen
Chemotherapy
Carboplatin & Topotecan
back to top |
Regimen
Chemotherapy
CE & Ipilimumab
back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
Docetaxel & Pertuzumab
back to top |
Regimen
Chemotherapy
Targeted therapy
Encorafenib monotherapy
back to top |
Regimen
Targeted therapy
EP & Ipilimumab
back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
- Concurrent thoracic radiation therapy
FEC & HP
back to top |
FEC & HP: Fluorouracil, Epirubicin, Cyclophosphamide, Herceptin (Trastuzumab), Pertuzumab
Regimen
Chemotherapy
Targeted therapy
FULV & Trimetrexate
back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Ixabepilone & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
MFL
back to top |
MFL: Methyl-lomustine (MeCCNU), 5-FU & LeucoVorin (Folinic acid)
Regimen
Chemotherapy
Mitoxantrone & Hydrocortisone
back to top |
Regimen
Chemotherapy
Hormonotherapy
PD & Pembrolizumab
back to top |
PD & Pembrolizumab: Pomalidomide, Dexamethasone, Pembrolizumab
Regimen
Targeted therapy
Immunotherapy
Pixantrone & Rituximab
back to top |
Regimen
Chemotherapy
Targeted therapy
TCHL (Taxotere)
back to top |
TCHL: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Lapatinib
Regimen
Chemotherapy
Targeted therapy
TCL (Taxotere)
back to top |
TCL: Taxotere (Docetaxel), Carboplatin, Lapatinib
Regimen
Chemotherapy
Targeted therapy
TEC
back to top |
TEC: Taxol (Paclitaxel), Epirubicin, Carboplatin
Regimen
Chemotherapy
TG+Bev
back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TL (Taxotere)
back to top |
TL: Taxotere (Docetaxel) & Lapatinib
Regimen
Chemotherapy
Targeted therapy
TX+Bev
back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab
Regimen
Chemotherapy
Targeted therapy
Vinorelbine & Hydrocortisone
back to top |